19:50 , Apr 20, 2018 |  Other News  |  Other News

Broad launches tool to identify vulnerabilities of cancer cells

The Broad Institute of MIT and Harvard University launched a publicly available online portal that allows any researcher worldwide to access and analyze data on genetic and pharmacologic dependencies of cancer cell lines, and associated...
23:47 , Apr 16, 2018 |  BC Extra  |  Tools & Techniques

Broad launches tool to identify vulnerabilities of cancer cells

The Broad Institute of MIT and Harvard University launched a publicly available online portal that allows any researcher worldwide to access and analyze data on genetic and pharmacologic dependencies of cancer cell lines, and associated...
03:45 , Apr 13, 2018 |  BC Innovations  |  Targets & Mechanisms

Meeting the burden

A major theme at this year’s AACR is the abundance of preclinical discovery driven by molecular signatures in patient samples, suggesting the research community is heeding the call for studies better grounded in human data,...
07:00 , Sep 10, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Hypoxia-inducible factor prolyl hydroxylase 2 (EGLN1; HIF-PH2; PHD2)

Cancer INDICATION: Cancer Mouse studies suggest PHD2 inhibition could help prevent or treat metastatic cancer. In a mouse model of breast cancer, systemic or tumor cell-specific PHD2 knockout decreased the number and size of lung...
07:00 , Jun 19, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Other

Indication Target/marker/pathway Summary Licensing status Publication and contact information Other Poisoning Hypoxia-inducible factor prolyl hydroxylase 1 (EGLN2; HIF-PH1; PHD1); PHD2 (EGLN1; HIF-PH2); PHD3 (EGLN3; HIF-PH3) Mouse studies suggest pan-PHD inhibitors could help prevent damage to...
07:00 , Oct 17, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Endocrine/metabolic disease

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Endocrine/metabolic disease Diabetes Hypoxia-inducible factor prolyl hydroxylase 3 (EGLN3; HIF-PH3; PHD3) Mouse studies suggest liver-specific inhibition of PHD3 could help treat type...
07:00 , Oct 10, 2013 |  BC Innovations  |  Cover Story

NSD2 momentum

Although NSD2 has been genetically linked to multiple myeloma for more than 15 years, drug discovery efforts against the target have lagged behind other histone methyltransferases including DOT1L and EZH2 . Now, a Novartis Institutes...
08:00 , Mar 7, 2013 |  BC Innovations  |  Cover Story

Assaying 2-HG's function

Although 2-hydroxyglutarate is a known marker for various cancers, including leukemia, 1,2 the metabolite's role in the disease remained unclear. Now, U.S. researchers have shown that the compound itself can drive leukemic transformation and that...
07:00 , Aug 30, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer Hypoxia-inducible factor prolyl hydroxylase 2 (EGLN1; HIF-PH2; PHD2) Mouse studies suggest PHD2 inhibitors could help improve the efficacy of chemotherapies. In Phd2-deficient mice with...
07:00 , Jun 21, 2012 |  BC Innovations  |  Distillery Techniques

Technology: Chemistry

Approach Summary Licensing status Publication and contact information Chemistry Combinatorial chemistry method for identifying boronic acid-based inhibitors of oxygenase enzymes A combinatorial chemistry method for identifying boronic acid-based inhibitors of oxygenase enzymes could help identify...